Core Points - The announcement from Chutian Technology indicates that the increase in total share capital is due to the conversion of convertible bonds into shares, leading to a dilution of the controlling shareholder's stake from 37.81% to 36.98% [2] Summary by Category - **Company Announcement** - Chutian Technology announced that the change in equity is a result of the conversion of convertible bonds, which has increased the total share capital [2] - The controlling shareholder, Changsha Chutian Investment Group Co., Ltd., experienced a passive dilution of its shareholding percentage [2] - **Shareholding Impact** - The controlling shareholder's stake decreased from 37.81% to 36.98%, crossing a 1% threshold, although the number of shares held did not change [2]

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-064 号 | | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | 2、本次权益变动不涉及要约收购，不会导致公司控股股东、实际控制人发 生变化，不会影响公司控制权稳定性，不会对公司治理结构及持续经营产生影响。 公司于 2025 年 11 月 5 日巨潮资讯网披露了《关于控股股东持股比例被动稀 释触及 1%整数倍的权益变动公告》（公告编号：2025-062 号），2025 年 11 月 3 日至 2025 年 11 月 4 日，因楚天转债转股导致公司总股本从 590,458,172 股增 加至 594,323,347 股，公司控股股东长沙楚天投资集团有限公司持股比例由 38.06%被动稀释至 37.81%，权益变动触及跨越 1%的整数倍。 自 2025 年 11 月 5 日至 2025 年 11 月 11 日，因公司可转换公司债券持续转 股导致公司总股本增加，公司控股股东在持股数量不变的情况下，持股比例被动 稀释。现将相关情况公告如下： | 1.基本情况 | | | --- | --- | ...

Core Insights - The Ministry of Industry and Information Technology (MIIT) of China has released two significant documents regarding the development of biological manufacturing, focusing on high-performance bioreactors and pilot-scale platforms, which aim to advance this emerging productive force in the industry [2][11]. Summary by Sections High-Performance Bioreactors - On November 4, MIIT published a notice listing the selected units for the innovation tasks related to high-performance bioreactors, with 9 key bioreactors and 23 leading universities, research institutes, and enterprises included in the list [2][4]. - Notable participants include companies and institutions such as Womei Biotech, the Chinese Academy of Sciences Tianjin Institute of Industrial Biotechnology, and East China University of Science and Technology [2][5]. Pilot-Scale Platforms - On November 10, MIIT announced the first batch of units selected for the biological manufacturing pilot-scale capability construction platform, comprising 43 units [2][8]. - Among these, 12 units received ratings of four stars or above, including Tianjin University Frontier Research Institute of Synthetic Biology and Beijing University of Chemical Technology Qinhuangdao Bohai Biological Industry Research Institute [3][9]. Key Participants - The list of selected units for high-performance bioreactors includes various leading organizations such as: - Womei Biotech - East China University of Science and Technology - Dibeier Biotechnology - Chutian Technology [5][6]. - The pilot-scale platform includes institutions like: - Beijing Zhaoyan Biotechnology Co., Ltd. - Tianjin University - Chinese Academy of Sciences Tianjin Institute of Industrial Biotechnology [9][10].

Group 1 - The core point of the announcement is that Chutian Technology has the right to redeem its convertible bonds if certain conditions are met, specifically if the stock price remains above 130% of the conversion price for at least 15 out of 30 consecutive trading days [1] - The company will redeem the convertible bonds at face value plus accrued interest, according to the terms outlined in the prospectus [1]

3、敬请广大投资者详细了解本次可转换公司债券的相关规定，并关注公司 后续公告，注意投资风险。 | 证券代码:300358 | 证券简称:楚天科技 | 公告编号：2025-063 号 | | --- | --- | --- | | 债券代码:123240 | 债券简称:楚天转债 | | 楚天科技股份有限公司 关于楚天转债可能满足赎回条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、自 2025 年 10 月 28 日至 2025 年 11 月 10 日，楚天科技股份有限公司（以 下简称"公司"）股票已有十个交易日的收盘价格不低于"楚天转债"当期转股 价格 8.00 元/股的 130%（含 130%，即 10.40 元/股）； 2、若在未来触发"楚天转债"的有条件赎回条款（即"在转股期内，如果 公司股票在任何连续三十个交易日中至少十五个交易日的收盘价格不低于当期 转股价格的 130%（含 130%）"），届时根据《楚天科技股份有限公司创业板向 不特定对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"） 中有条件赎回条款的 ...

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

关于控股股东持股比例被动稀释触及 1%整数倍的 | 证券代码:300358 | 证券简称:楚天科技 | 公告编号：2025-062 号 | | --- | --- | --- | | 债券代码:123240 | 债券简称:楚天转债 | | 楚天科技股份有限公司 变动方向 上升□ 下降☑ 一致行动人 有□ 无☑ 是否为第一大股东或实际控制人 是☑ 否□ 2.本次权益变动情况 股份种类（A 股、B 股等） 增持/减持股数（万股） 增持/减持比例（%） A 股 0 持股比例被动稀释 0.25% 合 计 0 持股比例被动稀释 0.25% 本次权益变动方式 通过证券交易所的集中交易 □ 通过证券交易所的大宗交易 □ 其他 ☑ （可转债转股被动稀释） 本次增持股份的资金来源 （可多选） 自有资金 □ 银行贷款 □ 其他金融机构借款 □ 股东投资款 □ 其他 □（请注明） 不涉及资金来源 ☑ 3. 本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 股份性质 本次变动前持有股份 本次变动后持有股份 股数(万股) 占总股本比例 (%) 股数(万股) 占总股本比例 (%) 合计持有股份 22470.6614 38.0 ...

Market Overview - The medical device sector experienced a slight decline of 0.1% on November 3, with Botao Bio leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Performers - N Danna saw a significant increase of 497.08%, closing at 102.10 with a trading volume of 67,900 shares and a transaction value of 665 million [1] - Weigao Blood Purification rose by 10.01%, closing at 42.30 with a trading volume of 11,500 shares [1] - Chutian Technology increased by 7.95%, closing at 12.09 with a trading volume of 829,300 shares and a transaction value of 978 million [1] Underperformers - Botao Bio led the decline with a drop of 8.32%, closing at 42.73 with a trading volume of 62,700 shares and a transaction value of 266 million [2] - ZhenDe Medical fell by 5.61%, closing at 89.67 with a trading volume of 289,000 shares [2] - Zhongke Meiying decreased by 3.99%, closing at 21.41 with a trading volume of 24,700 shares [2] Capital Flow - The medical device sector saw a net inflow of 300 million from institutional investors, while retail investors experienced a net outflow of 415 million [2][3] - Notable net inflows from institutional investors included ZhenDe Medical with 312 million and Furuishi with 69.51 million [3] - Retail investors showed significant outflows in stocks like Chutian Technology and East Fortune, with outflows of 4.48 million and 1.12 billion respectively [3]

Core Insights - The launch of innovative transdermal drug delivery equipment by Chutian Technology marks a significant breakthrough in China's high-end pharmaceutical equipment sector, breaking the long-standing foreign monopoly [1][2] - The collaboration between Chutian Technology and Beijing Tide Pharmaceutical is seen as a model for synergistic development between innovative formulations and high-end equipment [2] - Chutian Technology aims to increase its overseas revenue share to approximately 70%, driven by cost control, technological innovation, and efficiency advantages [3] Group 1: Company Developments - Chutian Technology has developed a series of production equipment for transdermal formulations, overcoming the dominance of international giants like Germany's HH [1] - The company has received recognition for its equipment as the first major technological equipment in Hunan Province and has been included in the Ministry of Industry and Information Technology's 2024 high-quality development initiative [1] - The company is restructuring its sales organization to prioritize international markets, establishing six regional divisions to manage both domestic and overseas markets [3] Group 2: Financial Performance - In the first half of 2025, Chutian Technology's overseas revenue reached 1.09 billion yuan, a year-on-year increase of 39.80%, with the Americas showing a remarkable growth of 318.99% [3] - The company's net profit attributable to shareholders for the first three quarters was 84.46 million yuan, significantly reversing losses compared to the previous year [3] - The company has implemented cost reduction measures, resulting in an 11.72% decrease in operating costs during the same period [3] Group 3: Industry Outlook - The global pharmaceutical equipment market is expected to grow at a stable rate of 5%-10% annually, presenting significant opportunities for Chinese companies to capture market share [3] - The next decade is viewed as a critical window for Chinese enterprises to expand in the global market, particularly in high-end equipment and intelligent transformation [3] - Industry experts believe that leading companies with strong technological foundations and financial capabilities will be the first to benefit from the industry's recovery [3]